Surv Biopharma

Executive Summary

Surv BioPharma is a Japanese bioventure company founded in 2022 from Kagoshima University, developing innovative gene therapies based on survivin-promoter-driven oncolytic viruses (Surv.m-CRA series) for cancer and in vivo gene therapy for hepatic diseases and diabetes. The company operates a drug discovery model, advancing candidates through early clinical development before out-licensing to major pharmaceutical partners. With ¥1 billion in total funding and a Phase 1 stage, Surv BioPharma focuses on selective cancer cell targeting and regenerative medicine. Despite limited public data, its core technology platform shows potential in oncology and immunology, positioning it for future partnerships.

Upcoming Catalysts (preview)

• Q2 2025Phase 1 clinical data readout for Surv.m-CRA oncolytic virus program40% success
• Q4 2025Out-licensing or partnership deal for hepatic disease gene therapy35% success
• Q3 2026IND filing for diabetes gene therapy candidate30% success